ALB and breast carcinoma: Albumin-encapsulated liposomes have emerged as a highly promising platform for delivering paclitaxel against breast cancer, combining the enhanced solubility and tumor-targeting features of nab-paclitaxel with the advantages of stability and controlled release of liposomal carriers [21, 75].